Clinical Trials

APEC1621E, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) MATCH - Phase 2 Subprotocol of Selumetinib (AZD6244 hydrogen sulfate) in patients with tumors harboring activating MAPK pathway mutations

Cancer Type

Multiple Sites, Non-Hodgkin's Lymphoma

ClinicalTrials.gov Identifier

NCT03213691

Principal Investigator

Anne–Marie Langevin MD

For more information about this study
View Details

About This Study

This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to other places in the body and have come back or do not respond to treatment. Selumetinib sulfate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.